Navigation Links
Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
Date:10/17/2007

BASINGSTOKE, England, Oct. 17 /PRNewswire-FirstCall/ -- Below is updated text of Shire plc's conference call notification. Please note U.S. release times and conference call times have been updated from an earlier release.

Shire PLC (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ) the global specialty biopharmaceutical company, will announce third quarter 2007 earnings on Thursday 1 November 2007.

Results press release will be issued at: 12:00 GMT / 08:00 ET

Investor meeting and conference call time: 14:30 GMT / 10:30 ET

Live conference call for investors:

Matthew Emmens, Chief Executive Officer and Angus Russell, Chief Financial Officer will host the live conference call for investors at 14:30 GMT/10:30 ET.

Please RSVP ssalah@shire.com (T: +44(0)1256-894-160) for this conference call.

The details of the conference call are as follows:

UK dial in: +44(0)800-953-0810,

US dial in: +1-866-789-2220,

International dial in: +44(0)1452-560-068,

Password/Conf ID: 20443623#

Live Webcast:*

http://www.shire.com/shire/InvestorRelations/events.jsp?tn=2&m1=33

Replay:

A replay of the presentation will be available for two weeks by phone and by webcast for one year. Details are as follows:

UK dial in: +44(0)800-953-1533,

US dial in: +1-866-247-4222,

International dial in: +44(0)1452-55-00-00,

Pin code: 20443623#

Webcast replay:*

http://www.shire.com/shire/InvestorRelations/events.jsp?tn=2&m1=33

* Email verification is required

Notes to editors

Shire PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.


'/>"/>
SOURCE Shire PLC
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Visions: Broderick says Wisconsin should be in top third in venture capital
2. Third Wave files countersuit vs. Digene in patent case
3. Third Wave reports net loss of $18.9M for 2006
4. Stratagene to pay Third Wave $10.75M in patent case
5. Third Wave responds to Digene patent lawsuit
6. Third Wave seeks approval of Cystic Fibrosis test
7. Third Wave Technologies to raise $14.9M through private debt
8. Venture capital above $6B for third straight quarter
9. Third Wave reports $5.2M third quarter loss
10. Third Wave reports another loss, stronger sales
11. Napier joins board of Third Wave Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... 2017 Ginkgo Bioworks, the organism company, ... in the synthesis and assembly of DNA. The ... pathway-length synthetic DNA into Ginkgo,s automated organism engineering ... construction of new organism designs for application across ... was founded to significantly increase the world,s capacity ...
(Date:1/19/2017)... Research and Markets has announced the addition ... Type, Application - Global Opportunity Analysis and Industry Forecast, 2014-2022" ... ... is projected to reach $15,737 million by 2022 from $6,521 in ... Omic technologies segment accounted for more than half ...
(Date:1/19/2017)... -- WuXi AppTec, a leading global pharmaceutical, biotechnology ... today announced that it has acquired HD Biosciences ... contract research organization (CRO). After completion of acquisition, ... WuXi, and will continue to focus on growing ... acquisition will further strengthen WuXi,s R&D capability from ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... of product vigilance software to leading biopharmaceutical and medical device manufacturers and regulators, ... a fully 21 CFR Part 11-compliant email client designed to provide product vigilance ...
Breaking Biology Technology:
(Date:1/6/2017)... NEWARK, Calif. , Jan. 5, 2017  Delta ... introduced its iris scanning technology for automotive at CESĀ® ... GNTX ) to demonstrate the use of ... to identify and authenticate the driver in a car, ... automobiles during the driving experience. Delta ID ...
(Date:1/4/2017)... VEGAS , Jan. 4, 2017  CES ... performance biometric sensor technology, today announced the launch ... sensor systems, the highly-accurate biometric sensor modules ... biometric technology, experience and expertise. The two ... Benchmark designed specifically for hearables, and Benchmark BW2.0, ...
(Date:12/22/2016)... , Dec. 20, 2016  As part of its ... the leading personal genetics company, recently released its latest children,s ... . The book focuses on the topics of inheritance and ... Science Standards (NGSS) taught in elementary school classrooms in the ... a series by illustrator Ariana Killoran , whose previous ...
Breaking Biology News(10 mins):